| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.06. | Mendus - Another encouraging ovarian cancer update | Mendus presented a positive clinical update for its Phase I ALISON trial in ovarian cancer at the 61st Annual American Society of Clinical Oncology conference (ASCO 2025). Importantly, the data demonstrated... ► Artikel lesen | |
| 07.05. | Mendus - No surprises in Q125 update | Mendus's Q125 results came in as expected, with management confirming that vididencel (in acute myeloid leukaemia, AML) is on track to be pivotal-stage ready from H225. Recent highlights include regulatory... ► Artikel lesen | |
| 06.05. | Mendus - Plans falling into place for vididencel pivotal study | Mendus's Q125 report included no surprises, with the company staying on track to secure large-scale GMP production of vididencel and Phase III readiness by H225, which we see as the most significant... ► Artikel lesen | |
| 06.05. | Mendus AB: Mendus AB Interim Report January - March 2025 | Phase 3 preparations and broader pipeline developments progress
In the first quarter of 2025, Mendus provided a summary of the supportive feedback from EMA and FDA related to the preparations for a... ► Artikel lesen | |
| 05.05. | Mendus AB: Mendus strengthens late-stage clinical development ability and appoints Dr Tariq Mughal as Chief Medical Officer | Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced the appointment of Tariq Mughal, MD FRCP FRCPath, as Chief Medical... ► Artikel lesen |
